Swiss NousCom raises €42 million

Switzerland-based NousCom AG, which is developing cancer vaccines, has completed a €42 million Series B financing round led by new investor Abingworth, along with 5AM Ventures. The funds will be used to advance two candidate neoantigen vaccines.

Full text available to subscribers only. Click here for information on subscribing to MedNous.